News

MilliporeSigma Expands End-to-End Biodevelopment Centers in North America, China and Europe

MilliporeSigma, a leading science and technology company, today announced the expansion of its end-to-end biodevelopment centers to meet increasing customer demand for its turnkey portfolio of bioprocessing products, manufacturing capabilities and industry leading technological expertise. The expansion, which includes the opening of two new process development centers in the U.S. and China, follows the commercial success of MilliporeSigma’s biodevelopment center in Martillac, France. The two new units will be located in close proximity to customers in the Shanghai and Boston…

80302_03_4X4INCH_BEAUTY_RGB300PPI

Qosina Adds New Y Connector Hemostasis Valves

Qosina is pleased to announce the addition of four new Y connector hemostasis valves (#80300-#80303) to its product line. Each hemostasis valve is equipped with a rotating male luer lock or male luer slip, and a female luer lock sideport. The Y connector gives the valve an ergonomic design for comfortable handling. The housing is made from a tinted polycarbonate material that minimizes discoloration during the sterilization process. The silicone gasket creates a seal for secure positioning when closed and…

Photo Members of the China SFDA tour the BTEC facility. (www.btec.ncsu.edu)

Saint-Gobain Opens New Maryland Facility to Manufacture Single-Use Systems for Cell Therapy

Saint-Gobain Performance Plastics’ Life Sciences Division is celebrating its move into the fast-growing cell therapy market with a new state-of-the-art facility that will manufacture specialty disposables for both the cell therapy and biotechnology markets. With material technology combined with expertise in custom design, Saint-Gobain Performance Plastics is uniquely positioned to offer solutions to the numerous challenges faced by cell therapy manufacturers today, contributing to the end goal of delivering effective therapies to more patients. Located in Gaithersburg, Maryland, the new…

Lonza to Divest Peptides Business and Operations in Braine-l’Alleud, Belgium, to PolyPeptide

Lonza and the PolyPeptide Group jointly announced today that PolyPeptide Laboratories Holding (PPL) has entered into a definitive agreement with Lonza Sales AG and Lonza AG (both 100% affiliates of Lonza Group AG) to acquire the peptides business and operations of Lonza in Braine-l’Alleud, Belgium. Lonza’s Braine facility, with approximately 280 employees, is the center for peptide chemical development and manufacturing within Lonza. The agreement is expected to close in the next weeks, subject to customary closing conditions. The acquisition…

Finesse® Solutions Launches Second Generation G3Lite+™ SmartController for Single-Use Bioreactor Systems

Finesse Solutions, Inc., a manufacturer of measurement and control solutions for life sciences process applications, announced the launch of its new G3Lite+ SmartController for upstream cell culture and fermentation. The G3Lite+ extends the capabilities of Finesse’s G3Lite product for all major brands of single-use bioreactors (50L to 2,000L operating volume) and single-use fermenters (30L to 300L operating volume). The G3Lite+ is now available for Mobius® CellReady, Thermo Scientific™ HyPerforma™ TK SUB, GE Xcellerex XDR, and Pall PadReactor® single-use vessels. The…

MilliporeSigma to Provide Provantage® End-to-End Services to Acticor Biotech SAS

MilliporeSigma today announced that it will provide its Provantage® End-to-End services to Acticor Biotech SAS for accelerated development and manufacturing of Acticor’s antibody fragment used for the primary treatment of ischemic stroke. MilliporeSigma’s Provantage® End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate progress of molecules into the clinic and toward commercialization. “Our Provantage® End-to-End solution will provide Acticor with a fast and flexible approach to development and clinical-scale manufacturing,” said Udit Batra, Member of…

MilliporeSigma Launches Parteck MXP Excipient for Increased Solubility

MilliporeSigma, a leading science and technology company, today introduced Parteck® MXP, a polyvinyl alcohol-based excipient that enhances solubility of a wide range of active pharmaceutical ingredients (APIs) with poor bioavailability. Parteck® MXP excipient maintains stability at temperatures above 200 degrees Celsius, making it well-suited for hot melt extrusion (HME), a process used by drug manufacturers to enhance the solubility and bioavailability of APIs. The new excipient can achieve drug loads of 30% or more, while other excipients may be limited…

MilliporeSigma Expands Distribution Agreement with Roche in Canada

MilliporeSigma today announced an expansion of its distribution alliance with Roche to include the polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products of Kapa Biosystems, a company acquired by Roche in 2015. The addition of the Kapa portfolio strengthens MilliporeSigma’s existing distribution relationship with Roche by providing one of the most complementary suites of high-performance tools for PCR and qPCR in the industry today. “The alliance extension with Roche will offer our customers greater access to novel products…

Natrix Separations Announces Collaboration Agreements with Merck and Sanofi for the Development of Membrane-Based Protein A Purification Platform

Natrix Separations Inc. today announced development agreements with Merck, known as MSD outside the United States and Canada, and Sanofi to advance Natrix’s new membrane-based Protein A platform for antibody purification. The Natrix Protein A platform is expected to pave the way for a new generation of more flexible, highly-productive single-use based biologics production facilities for both batch and continuous processes. The platform is predicted to increase purification productivity by a factor of up to 10x, while reducing both cost…

MilliporeSigma Collaborates with Evotec for Faster Target Identification Solution

MilliporeSigma today announced that it has entered into a set of agreements with Evotec AG, whereby Evotec AG will provide screening services for Merck’s collection of genetic reagents such as CRISPR and shRNA libraries. Combining access to these libraries with Evotec’s screening expertise offers an accelerated pathway to explore and identify new drug targets. “Drug discovery starts with the identification of new targets, a process that can be time- and labor-intensive,” said Theresa Creasey, Head of Applied Solutions Strategic Marketing &…